pre-IPO PHARMA

COMPANY OVERVIEW

Meissa Vaccines is a pharmaceutical start-up company focused on advancement of unmet vaccines against viruses that cause serious human diseases, such as respiratory syncytial virus (RSV). Our innovative platform technology for viral genetic engineering can be applied to multiple pathogens.


LOCATION

  • South San Francisco, CA, USA

  • THERAPEUTIC AREAS

  • Vaccines

  • WEBSITE

    https://www.meissavaccines.com


    CAREER WEBSITE

    https://www.meissavaccines.com/jobs.html


    SOCIAL MEDIA


    INVESTORS

    fundrx


    PRESS RELEASES


    Aug 8, 2023

    Meissa Vaccines Announces Positive Clinical Data for the First RSV Vaccine Designed to Protect Infants and Toddlers


    Nov 7, 2022

    Meissa Vaccines Announces Positive Interim Clinical Data for Its Intranasal Live Attenuated Respiratory Syncytial Virus (RSV) Vaccine Candidate for Infants


    Jul 27, 2022

    Meissa Vaccines Presented at The White House Summit on the Future of COVID-19 Vaccines


    Jul 11, 2022

    Meissa Vaccines Appoints Frank Glavin Chief Executive Officer


    Jun 30, 2021

    Meissa Vaccines Begins Study of RSV Vaccine Candidate in Seronegative Children


    For More Press Releases


    Google Analytics Alternative